Trial Profile

A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Feb 2026 According to a Tyra Biosciences media release, data from this study will be presented at the 2026 ASCO Genitourinary (GU) Cancers Symposium (ASCO GU). The meeting is being heldFebruary 27, 2026, 11:30 AM to12:45 PM PST, in San Francisco, California.
05 Nov 2025 According to Tyra Biosciences media release, the company remains on track to report interim results from the safety sentinel cohort in first half of 2026.
14 Aug 2025 According to Tyra Biosciences media release, R&D expenses for the three months ended June 30, 2025 were $24.3 million compared to $18.0 million for the same period in 2024. The increase was associated with start-up and enrollment activities for BEACH301, SURF302 and SURF431.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com